000			04254nam a22003615i 4500
988			_aEbook_one2one
999			_c76711 _d76711 _x1
001			76711
003			ES-MaUEC
005			20240611040132.0
007			cr nn 008mamaa
008			131209s2014 it | s |||| 0|eng d
020			_a9788847053137
024	7		_a10.1007/978-88-470-5313-7 _2doi
040			_aES-MaUEC
050		4	_aRM302.5 _b.T75 2014a EB
082	0	4	_a610
100	1		_aTridente, Giuseppe _985977 _0Local _0http://id.loc.gov/authorities/names/n86068291 _1http://viaf.org/viaf/232989550
245	1	0	_aAdverse Events with Biomedicines : _bPrevention Through Understanding _cby Giuseppe Tridente.
264		1	_aMilano _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XXX, 633 páginas)
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart I General Aspects: 1 Introduction -- 2 Adverse drug events to biomedicines -- 3 Systemic syndromes caused by biomedicines -- Part II Monoclonal antibodies: 4 Monoclonal antibodies -- 5 Abciximab -- 6 Adalimumab -- 7 Alemtuzumab -- 8 Basiliximab -- 9 Belimumab -- 10 Bevacizumab -- 11 Brentuximab -- 12 Canakinumab -- 13 Catumaxomab -- 14.Âårtolizumab -- 15 Cetuximab -- 16 Daclizumab -- 17 Denosumab -- 18Âţulizumab -- 19 Edrecolomab -- 20 Efalizumab -- 21 Gemtuzumab -- 22 Golimumab -- 23 Ibritumomab -- 24 Infliximab -- 25 Ipilimumab -- 26 Muromonab -- 27 Natalizumab -- 28 Nimotuzumab -- 29 Ofatumumab -- 30 Omalizumab -- 31 Palivizumab -- 32 Panitumumab -- 33 Pertuzumab -- 34 Ranibizumab -- 35 Rituximab -- 36 Tocilizumab -- 37 Tositumomab -- 38 Trastuzumab -- 39 Ustekinumab -- Part III Fusion proteins: 40 Fusion proteins -- 41 Abatacept -- 42 Aflibercept -- 43 Alefacept -- 44 Belatacept -- 45 Etanercept -- 46 Rilonacept -- 47 Romiplostim -- Part IV CytokinesÂ{uA834}8 Cytokines -- 49 Interleukins -- 50 Denileukin-diftitox -- 51 Anakinra -- 52 Interferons -- 53 Hemopoietic stimulatory factors -- 54 Myelopoietic stimulatory factors -- 55 Thrombopoietic stimulatory factor -- 56 Pluripotent growth factors -- 57 Epidermal growth factors -- Part V Overview: 58 Biomedicines as adverse event inducers -- 59 Conclusions and perspectives.
520			_aThis monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicinesâ€{u0880}{u0B6F}noclonal antibodies, fusion proteins, and cytokines â€{u0D28}at have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered. Electronic data sheets, downloadable from the Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies.
650		7	_aMedicamentos _xEfectos secundarios _9168753
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-88-470-5313-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12823296 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aR-RZ EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11552505 _z06-04-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _git _h0